Literature DB >> 22607896

Meningococcal disease: clinical presentation and sequelae.

David Pace1, Andrew J Pollard.   

Abstract

The clinical spectrum of invasive meningococcal disease is diverse with meningitis and/or septicaemia being the commonest modes of presentation. The severity of manifestations of meningococcal infection ranges from bacteraemia, associated with mild non-specific symptoms, to fulminant sepsis with multiorgan failure and death in approximately 10-15% of cases. Localised infections (such as conjunctivitis or septic arthritis) as well as chronic disease may be the sole clinical manifestations but can also lead to disseminated fulminant disease. Among survivors, disabling long-term sequelae can complicate meningococcal disease and result in potentially devastating effects on the quality of life of survivors, most of whom are infants, children and adolescents. The only rational approach to the prevention of meningococcal disease and the associated human suffering is through vaccination.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22607896     DOI: 10.1016/j.vaccine.2011.12.062

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  90 in total

1.  Painful knees and hearing-loss: a rare presentation of meningococcal disease.

Authors:  Vivienne Kahlmann; Celina Alves; Johannes Koeleman; Lindy-Anne Korswagen
Journal:  BMJ Case Rep       Date:  2016-06-29

2.  Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults.

Authors:  Ira L Leeds; Vasanthkumar Namasivayam; Assanatou Bamogo; Prithvi Sankhla; Winter M Thayer
Journal:  Am J Prev Med       Date:  2018-12-17       Impact factor: 5.043

3.  Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody.

Authors:  Enrico Malito; Marco Biancucci; Agnese Faleri; Ilaria Ferlenghi; Maria Scarselli; Giulietta Maruggi; Paola Lo Surdo; Daniele Veggi; Alessia Liguori; Laura Santini; Isabella Bertoldi; Roberto Petracca; Sara Marchi; Giacomo Romagnoli; Elena Cartocci; Irene Vercellino; Silvana Savino; Glen Spraggon; Nathalie Norais; Mariagrazia Pizza; Rino Rappuoli; Vega Masignani; Matthew James Bottomley
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-17       Impact factor: 11.205

4.  Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine.

Authors:  Shannon L Harris; Cuiwen Tan; John Perez; David Radley; Kathrin U Jansen; Annaliesa S Anderson; Thomas R Jones
Journal:  NPJ Vaccines       Date:  2020-01-29       Impact factor: 7.344

Review 5.  Invasive meningococcal disease in the 21st century—an update for the clinician.

Authors:  Rachel Dwilow; Sergio Fanella
Journal:  Curr Neurol Neurosci Rep       Date:  2015-03       Impact factor: 5.081

Review 6.  Review of meningococcal vaccines with updates on immunization in adults.

Authors:  Yorgo C Zahlanie; Moza M Hammadi; Soha T Ghanem; Ghassan S Dbaibo
Journal:  Hum Vaccin Immunother       Date:  2014-02-05       Impact factor: 3.452

7.  Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.

Authors:  Sarah A Mbaeyi; Catherine H Bozio; Jonathan Duffy; Lorry G Rubin; Susan Hariri; David S Stephens; Jessica R MacNeil
Journal:  MMWR Recomm Rep       Date:  2020-09-25

Review 8.  MenB-FHbp Meningococcal Group B Vaccine (Trumenba®): A Review in Active Immunization in Individuals Aged ≥ 10 Years.

Authors:  Matt Shirley; Muhamed-Kheir Taha
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

Review 9.  Challenges and opportunities for meningococcal vaccination in the developing world.

Authors:  Rouba Shaker; Danielle Fayad; Ghassan Dbaibo
Journal:  Hum Vaccin Immunother       Date:  2018-02-23       Impact factor: 3.452

10.  Hospital admission with infection during childhood and risk for psychotic illness--a population-based cohort study.

Authors:  Åsa Blomström; Håkan Karlsson; Anna Svensson; Thomas Frisell; Brian K Lee; Henrik Dal; Cecilia Magnusson; Christina Dalman
Journal:  Schizophr Bull       Date:  2013-12-23       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.